Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Alkylating
  • Biomarkers, Tumor
  • Dacarbazine
  • Lung Neoplasms
  • O(6)-Methylguanine-DNA Methyltransferase
  • Small Cell Lung Carcinoma

abstract

  • Temozolomide has activity in relapsed SCLC, particularly for brain metastases. Response to temozolomide may correlate with MGMT methylation in SCLC.

publication date

  • February 15, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-11-2059

PubMed ID

  • 22228633

Additional Document Info

start page

  • 1138

end page

  • 45

volume

  • 18

number

  • 4